Arcellx (ACLX) Accounts Payables (2021 - 2025)
Arcellx's quarterly Accounts Payables came in at $5.6 million in Q4 2025, up 166.16% year-on-year from $2.1 million in Q4 2024, and up 32.64% quarter-over-quarter from $4.2 million in Q3 2025.
Arcellx has reported Accounts Payables for 5 years, with the latest figure at $5.6 million in Q4 2025.
- For the quarter ending Q4 2025, Accounts Payables rose 166.16% year-over-year to $5.6 million; the trailing twelve-month figure through Dec 2025 stood at $5.6 million (up 166.16% YoY), and the FY2025 full-year result was $5.6 million, up 166.16% from the prior year.
- Accounts Payables for Q4 2025 stood at $5.6 million, up from $4.2 million in the prior quarter.
- The five-year high for Accounts Payables was $9.1 million in Q4 2022, with the low at $1.3 million in Q4 2021.
- Average Accounts Payables over 5 years is $4.4 million, with a median of $4.4 million recorded in 2025.
- Year-over-year, Accounts Payables surged 579.14% in 2022 and slumped 71.07% in 2023.
- Tracing ACLX's Accounts Payables over 5 years: stood at $1.3 million in 2021, then surged by 579.14% to $9.1 million in 2022, then tumbled by 71.07% to $2.6 million in 2023, then dropped by 20.01% to $2.1 million in 2024, then jumped by 166.16% to $5.6 million in 2025.
- The last three Accounts Payables figures came in at $5.6 million (Q4 2025), $4.2 million (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 5.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.58 Mn |
| Sep 30, 2025 | 4.20 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 4.37 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 5.99 Mn |
| Jun 30, 2024 | 4.87 Mn |
| Mar 31, 2024 | 3.10 Mn |
| Dec 31, 2023 | 2.62 Mn |
| Sep 30, 2023 | 7.19 Mn |
| Jun 30, 2023 | 5.69 Mn |
| Mar 31, 2023 | 4.53 Mn |
| Dec 31, 2022 | 9.05 Mn |
| Sep 30, 2022 | 2.96 Mn |
| Jun 30, 2022 | 7.56 Mn |
| Mar 31, 2022 | 1.87 Mn |
| Dec 31, 2021 | 1.33 Mn |